Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2006

View Archived Issues

Proof-of-concept milestone in phase Ib study of HCV-796

Milestone achieved in Evotec and Takeda's Alzheimer's disease collaboration

Chromos advances development of CHR-1103

NTx-265 yields recovery of lost neurological function in rodent model of stroke

Overcoming TKI resistance via ADAM inhibition

NNZ-2566 set to begin phase II for traumatic brain injury in 2007

Algeta and Affibody to develop novel targeted radiotherapeutics

New imaging agents for ocular disorders and cancer disclosed in recent GE and Yeda patents

HIV integrase inhibitor 364735 completes initial phase I study

Recent Tanabe and Neurogen patents report novel analgesic agents

Recent Tanabe and Dainippon patents describe new antidiabetic agents

Recent Tibotec and Pfizer patents report novel therapeutic agents for HIV infection

5F-203 triggers single-strand DNA breaks and cell cycle arrest in MCF7 cells

Favorable pharmacokinetics in monkeys warrant further development of Dioxolane T

TMC-278-ketoconazole interaction detailed in healthy subjects

Pharmacokinetics of apricitabine similar in HIV-positive and -negative subjects

Vicriviroc pharmacokinetics, phase II results reported

New data on TMC-114, TMC-125 and their combination presented

Safety and activity of fontolizumab evaluted in Crohn's disease patients

BB-10153 induces high rate of normal flow in ST elevation myocardial infarction

Actonel approved for men with osteoporosis

Remicade approved for expanded indication in psoriatic arthritis

Vasovist recommended for approval in Australia

Abilify Discmelt launched in U.S.

Plavix approved for use in patients with STEMI

Keppra approved in Europe for newly diagnosed epilepsy patients

Rhucin MAA accepted for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...